@article{97cf2ae66cee4eeeb8ae8fff7b83fd00,
title = "Lessons for reviewing clinical trials using induced pluripotent stem cells: Examining the case of a first-in-human trial for age-related macular degeneration",
keywords = "age-related macular degeneration, AMD, committee meeting minutes, direct benefit, first-in-human trial, induced pluripotent stem cell, iPSC, protecting research participants, reasonable accommodation, review committee, risk assessment, subject selection",
author = "Kayo Takashima and Yusuke Inoue and Shimon Tashiro and Kaori Muto",
note = "Funding Information: This research was supported by the Highway Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development (AMED). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funded writing assistance (English editing service) for this manuscript was supported by AMED.",
year = "2018",
month = mar,
doi = "10.2217/rme-2017-0130",
language = "English",
volume = "13",
pages = "123--128",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "2",
}